Sai-Hong I. Ou: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

1

Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations

Drilon, Alexander, Ou, Sai-Hong I., Cho, Byoung Chul, Kim, Dong-Wan, Lee, Jeeyun, Lin, Jessica J., Zhu, Viola W, Ahn, Myung-Ju, Camidge, D. Ross, Nguyen, Judy, Zhai, Dayong, Deng, Wei, Huang, Zhongdon

Journal:

Cancer Discovery

Year:

2018

Language:

english

File:

PDF, 5.57 MB

english, 2018

2

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, Eunice L., Bang, Yung-Jue, Camidge, D. Ross, Shaw, Alice T., Solomon, Benjamin, Maki, Robert G., Ou, Sai-Hong I., Dezube, Bruce J., Jänne, Pasi A., Costa, Daniel B., Varella-Garcia, Marileila, K

Journal:

Boston Medical and Surgical Journal

Year:

2010

Language:

english

File:

PDF, 1.11 MB

english, 2010

3

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Peters, Solange, Camidge, D. Ross, Shaw, Alice T., Gadgeel, Shirish, Ahn, Jin S., Kim, Dong-Wan, Ou, Sai-Hong I., Pérol, Maurice, Dziadziuszko, Rafal, Rosell, Rafael, Zeaiter, Ali, Mitry, Emmanuel, Go

Journal:

New England Journal of Medicine

Year:

2017

Language:

english

File:

PDF, 291 KB

english, 2017

4

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

Ou, Sai-Hong Ignatius, Gadgeel, Shirish M., Barlesi, Fabrice, Yang, James Chih-Hsin, De Petris, Luigi, Kim, Dong-Wan, Govindan, Ramaswamy, Dingemans, Anne-Marie, Crino, Lucio, Léna, Hervé, Popat, Sanj

Journal:

Year:

2020

Language:

english

File:

PDF, 1.07 MB

english, 2020

5

Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer

Shaw, Alice T., Ou, Sai-Hong I., Bang, Yung-Jue, Camidge, D. Ross, Solomon, Benjamin J., Salgia, Ravi, Riely, Gregory J., Varella-Garcia, Marileila, Shapiro, Geoffrey I., Costa, Daniel B., Doebele, Ro

Journal:

New England Journal of Medicine

Year:

2014

Language:

english

File:

PDF, 673 KB

english, 2014

6

Rare subtypes of adenocarcinoma of the lung

Ou, Sai-Hong Ignatius, Kawaguchi, Tomoya, Soo, Ross A, Kitaichi, Masanori

Journal:

Expert Review of Anticancer Therapy

Year:

2011

Language:

english

File:

PDF, 1.58 MB

english, 2011

7

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable

Reungwetwattana, Thanyanan, Liang, Ying, Zhu, Viola, Ou, Sai-Hong Ignatius

Journal:

Year:

2016

Language:

english

File:

PDF, 1.01 MB

english, 2016

8

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Drilon, Alexander, Siena, Salvatore, Ou, Sai-Hong Ignatius, Patel, Manish, Ahn, Myung Ju, Lee, Jeeyun, Bauer, Todd M., Farago, Anna F., Wheler, Jennifer J., Liu, Stephen V., Doebele, Robert, Giannetta

Journal:

Cancer Discovery

Year:

2017

Language:

english

File:

PDF, 1.09 MB

english, 2017

9

OA10.01 Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade

Riess, Jonathan, Gandara, David R., Frampton, Garrett, Cheng, Mingshan, Lara, Primo, Kelly, Karen, Ye, Chunting, Madison, Russell, Peled, Nir, Bufill, Jose, Dy, Grace, Ou, Sai-Hong, Cross, Darren, Bul

Journal:

Journal of Thoracic Oncology

Year:

2017

Language:

english

File:

PDF, 175 KB

english, 2017

10

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation

Klempner, Samuel J., Gowen, Kyle, Lee, Thomas K., Zhu, Viola W., Schrock, Alexa B., Miller, Vincent A., Ali, Siraj M., Ou, Sai-Hong Ignatius

Journal:

Year:

2018

Language:

english

File:

PDF, 2.70 MB

english, 2018

11

Liquid Biopsy to Identify Actionable Genomic Alterations

Ou, Sai-Hong Ignatius, Nagasaka, Misako, Zhu, Viola W.

Journal:

American Society of Clinical Oncology Educational Book

Year:

2018

Language:

english

File:

PDF, 649 KB

english, 2018

12

Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer

Zhu, Viola W., Klempner, Samuel J., Ou, Sai-Hong Ignatius

Journal:

Trends in Cancer

Year:

2019

Language:

english

File:

PDF, 1.97 MB

english, 2019

13

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Nagasaka, Misako, Li, Yiwei, Sukari, Ammar, Ignatius Ou, Sai-Hong, Najeeb Al-Hallak, Mohammed, Azmi, Asfar S

Journal:

Cancer Treatment Reviews

Year:

2020

File:

PDF, 438 KB

2020

14

Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618

Susanne M. Arnold, James Moon, Stephen K. Williamson, James N. Atkins, Sai-Hong I. Ou, Michael LeBlanc, Susan G. Urba

Journal:

Investigational New Drugs

Year:

2011

Language:

english

File:

PDF, 159 KB

english, 2011

15

Small-Cell Lung Cancer in Never-Smokers: A Case Series With Information on Family History of Cancer and Environmental Tobacco Smoke

Yu Kurahara, Tomoya Kawaguchi, Kazunobu Tachibana, Shinji Atagi, Seiji Hayashi, Masanori Kitaichi, Sai-Hong I. Ou, Minoru Takada

Journal:

Clinical Lung Cancer

Year:

2012

Language:

english

File:

PDF, 1.47 MB

english, 2012

16

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Alice T Shaw, Beow Y Yeap, Benjamin J Solomon, Gregory J Riely, Justin Gainor, Jeffrey A Engelman, Geoffrey I Shapiro, Daniel B Costa, Sai-Hong I Ou, Mohit Butaney, Ravi Salgia, Robert G Maki, Marilei

Journal:

The Lancet Oncology

Year:

2011

Language:

english

File:

PDF, 250 KB

english, 2011

17

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

James Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, Te-Chun Hsia, Chun-Ming Tsai, Sai-Hong Ignatius Ou, Chung-Jen Yu, Gee-Chen Chang, Ching-Liang Ho, Lecia V Sequist, Arkadiusz Z Dudek, Mehdi Shahidi, Xi

Journal:

The Lancet Oncology

Year:

2012

Language:

english

File:

PDF, 301 KB

english, 2012

18

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim, Ravi Salgia, Panagiotis Fidias, J

Journal:

The Lancet Oncology

Year:

2012

Language:

english

File:

PDF, 310 KB

english, 2012

19

Chemotherapy is Beneficial for Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Patients Aged 70-74, 75-79, and 80 or Older in Japan

Tomoya Kawaguchi, Akihiro Tamiya, Atsuhisa Tamura, Masamichi Arao, Ryusei Saito, Akihide Matsumura, Sai-Hong I. Ou, Taro Tamura

Journal:

Clinical Lung Cancer

Year:

2012

Language:

english

File:

PDF, 444 KB

english, 2012

20

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

Sai-Hong Ignatius Ou

Journal:

Critical Reviews in Oncology/Hematology

Year:

2012

Language:

english

File:

PDF, 556 KB

english, 2012

21

Capedtabine in Advanced Gastric or Oesophagogastric Cancer

Sai-Hong Ignatius Ou, Randall F. Holcombe

Journal:

Year:

2007

Language:

english

File:

PDF, 48 KB

english, 2007

22

Phase II Trial of Sequential Chemotherapy Followed by Chemoradiation, Surgery, and Postoperative Chemotherapy for the Treatment of Stage IIIA/IIIB Non-Small-Cell Lung Cancer

Prudence Lam, Stuart Berman, Robert Thurer, Simon Ashiku, Malcolm DeCamp, Michael Goldstein, Susan Schumer, Balazs Halmos, Daniel Karp, Danielle Coute, Mark Bergman, Cynthia Boyd-Sirard, Sai-Hong Ou,

Journal:

Clinical Lung Cancer

Year:

2006

Language:

english

File:

PDF, 179 KB

english, 2006

23

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

Ou, Sai-Hong Ignatius

Journal:

Drug Design Development and Therapy

Year:

2011

Language:

english

File:

PDF, 1.05 MB

english, 2011

24

ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

Ou, Sai-Hong Ignatius, Tan, Jackie, Yen, Yun, Soo, Ross A

Journal:

Expert Review of Anticancer Therapy

Year:

2012

Language:

english

File:

PDF, 2.26 MB

english, 2012

25

Identification of ROS1 rearrangement in gastric adenocarcinoma

Lee, Jeeyun, Lee, Seung Eun, Kang, So Young, Do, In-Gu, Lee, Sujin, Ha, Sang Yun, Cho, Jeonghee, Kang, Won Ki, Jang, Jiryeon, Ou, Sai-Hong Ignatius, Kim, Kyoung-Mee

Journal:

Year:

2013

Language:

english

File:

PDF, 598 KB

english, 2013

26

Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer

Ou, Sai-Hong Ignatius

Journal:

Expert Review of Anticancer Therapy

Year:

2012

Language:

english

File:

PDF, 1.27 MB

english, 2012

27

Human papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature

Hasegawa, Yoshikazu, Ando, Masahiko, Kubo, Akihito, Isa, Shun-ichi, Yamamoto, Satomi, Tsujino, Kazuyuki, Kurata, Takayasu, Ou, Sai-Hong I., Takada, Minoru, Kawaguchi, Tomoya

Journal:

Year:

2014

Language:

english

File:

PDF, 1019 KB

english, 2014

28

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments

Locati, Laura D., Licitra, Lisa, Agate, Laura, Ou, Sai-Hong I., Boucher, Andree, Jarzab, Barbara, Qin, Shukui, Kane, Madeleine A., Wirth, Lori J., Chen, Connie, Kim, Sinil, Ingrosso, Antonella, Pithav

Journal:

Year:

2014

Language:

english

File:

PDF, 562 KB

english, 2014

29

Heart rate decrease during crizotinib treatment and potential correlation to clinical response

Ou, Sai-Hong Ignatius, Tong, Wilson P., Azada, Michele, Siwak-Tapp, Christina, Dy, Joni, Stiber, Jonathan A.

Journal:

Year:

2013

Language:

english

File:

PDF, 96 KB

english, 2013

30

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

Jänne, Pasi A, Ou, Sai-Hong I, Kim, Dong-Wan, Oxnard, Geoffrey R, Martins, Renato, Kris, Mark G, Dunphy, Frank, Nishio, Makoto, O'Connell, Joseph, Paweletz, Cloud, Taylor, Ian, Zhang, Hui, Goldberg, Z

Journal:

The Lancet Oncology

Year:

2014

Language:

english

File:

PDF, 277 KB

english, 2014

31

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

Rosell, Rafael, Karachaliou, Niki, Wolf, Juergen, Ou, Sai-Hong Ignatius

Journal:

The Lancet Respiratory Medicine

Year:

2014

Language:

english

File:

PDF, 211 KB

english, 2014

32

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient

Lu, Stephanie, Azada, Michele C., Ou, Sai-Hong Ignatius

Journal:

Year:

2015

Language:

english

File:

PDF, 1.08 MB

english, 2015

33

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib

Ou, Sai-Hong Ignatius, Greenbowe, Joel, Khan, Ziad U., Azada, Michele C., Ross, Jeffrey S., Stevens, Phil J., Ali, Siraj M., Miller, Vincent A., Gitlitz, Barbara

Journal:

Year:

2015

Language:

english

File:

PDF, 1.08 MB

english, 2015

34

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non–Small-Cell Lung Cancer: A Mini-Review

Klempner, Samuel J., Ignatius Ou, Sai-Hong, Costa, Daniel B., VanderLaan, Paul A., Sanford, Eric M., Schrock, Alexa, Gay, Laurie, Ali, Siraj M., Miller, Vincent A.

Journal:

Clinical Lung Cancer

Year:

2015

Language:

english

File:

PDF, 1.10 MB

english, 2015

35

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors

Chin, Leow Pay, Soo, Ross A., Soong, Richie, Ou, Sai-Hong I.

Journal:

Journal of Thoracic Oncology

Year:

2012

Language:

english

File:

PDF, 379 KB

english, 2012

36

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Ou, Sai-Hong Ignatius, Kwak, Eunice L., Siwak-Tapp, Christina, Dy, Joni, Bergethon, Kristin, Clark, Jeffrey W., Camidge, D. Ross, Solomon, Benjamin J., Maki, Robert G., Bang, Yung-Jue, Kim, Dong-Wan,

Journal:

Journal of Thoracic Oncology

Year:

2011

Language:

english

File:

PDF, 1.43 MB

english, 2011

37

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib

Ou, Sai-Hong Ignatius, Klempner, Samuel J., Greenbowe, Joel R., Azada, Michele, Schrock, Alexa B., Ali, Siraj M., Ross, Jeffrey S., Stephens, Philip J., Miller, Vincent A.

Journal:

Journal of Thoracic Oncology

Year:

2014

Language:

english

File:

PDF, 938 KB

english, 2014

38

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang, James C-H, Sequist, Lecia V, Geater, Sarayut Lucien, Tsai, Chun-Ming, Mok, Tony Shu Kam, Schuler, Martin, Yamamoto, Nobuyuki, Yu, Chong-Jen, Ou, Sai-Hong I, Zhou, Caicun, Massey, Daniel, Zazulin

Journal:

The Lancet Oncology

Year:

2015

Language:

english

File:

PDF, 381 KB

english, 2015

39

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-Î±-, NTRK1-) Non-Small Cell Lung Cancer Globally?

Ou, Sai-Hong Ignatius, Soo, Ross A., Kubo, Akihito, Kawaguchi, Tomoya, Ahn, Myung-Ju

Journal:

Frontiers in Oncology

Year:

2014

Language:

english

File:

PDF, 519 KB

english, 2014

40

Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling

Ou, Sai-Hong Ignatius, Chalmers, Zachary R., Azada, Michele C., Ross, Jeffrey S., Stephens, Philip J., Ali, Siraj M., Miller, Vincent A.

Journal:

Year:

2015

Language:

english

File:

PDF, 859 KB

english, 2015

41

Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management

Ou, Sai-Hong Ignatius, Klempner, Samuel J., Azada, Michele C., Rausei-Mills, Veronica, Duma, Christopher

Journal:

Year:

2015

Language:

english

File:

PDF, 2.79 MB

english, 2015

42

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression

Ou, Sai-Hong Ignatius, Milliken, Jeffrey C., Azada, Michele C., Miller, Vincent A., Ali, Siraj M., Klempner, Samuel J.

Journal:

Year:

2015

Language:

english

File:

PDF, 688 KB

english, 2015

43

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy

Soo, Ross A, Kawaguchi, Tomoya, Loh, Marie, Ou, Sai-Hong I, Shieh, Marie P, Cho, Byoung-Chul, Mok, Tony S, Soong, Richie

Journal:

Future Oncology

Year:

2012

Language:

english

File:

PDF, 577 KB

english, 2012

44

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy

Klempner, Samuel J., Bordoni, Rodolfo, Gowen, Kyle, Kaplan, Henry, Stephens, Philip J., Ou, Sai-Hong Ignatius, Ali, Siraj M.

Journal:

Year:

2015

Language:

english

File:

PDF, 238 KB

english, 2015

45

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

Kodityal, Sandeep, Elvin, Julia A., Squillace, Rachel, Agarwal, Nikita, Miller, Vincent A., Ali, Siraj M., Klempner, Samuel J., Ou, Sai-Hong Ignatius

Journal:

Year:

2016

Language:

english

File:

PDF, 406 KB

english, 2016

46

The Effect of Tumor Size on Non-Size-Based Descriptors in Staging of Stage I Non-small Cell Lung Cancer: Response

Ou, Sai-Hong Ignatius, Zell, Jason A.

Journal:

Year:

2009

Language:

english

File:

PDF, 212 KB

english, 2009

47

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled Analysis of the Literature

Tsujino, Kazuyuki, Kurata, Takayasu, Yamamoto, Satomi, Kawaguchi, Tomoya, Kubo, Akihito, Isa, Shunichi, Hasegawa, Yoshikazu, Ou, Sai-Hong Ignatius, Takada, Minoru, Ando, Masahiko

Journal:

Journal of Thoracic Oncology

Year:

2013

Language:

english

File:

PDF, 723 KB

english, 2013

48

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib

Ou, Sai-Hong Ignatius, Azada, Michele, Dy, Joni, Stiber, Jonathan A.

Journal:

Journal of Thoracic Oncology

Year:

2011

Language:

english

File:

PDF, 1.24 MB

english, 2011

49

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib

Ou, Sai-Hong Ignatius, Azada, Michele, Hsiang, David J., Herman, June M., Kain, Tatiana S., Siwak-Tapp, Christina, Casey, Cameron, He, Jie, Ali, Siraj M., Klempner, Samuel J., Miller, Vincent A.

Journal:

Journal of Thoracic Oncology

Year:

2014

Language:

english

File:

PDF, 2.27 MB

english, 2014

50

Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations

Reungwetwattana, Thanyanan, Ou, Sai-Hong Ignatius

Journal:

Journal of Thoracic Oncology

Year:

2016

Language:

english

File:

PDF, 160 KB

english, 2016